Loading clinical trials...
Loading clinical trials...
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
PPD Virtual
Wilmington, North Carolina, United States
Jüdisches Krankenhaus Berlin
Berlin, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
UKGM - Universitätsklinikum Gießen und Marburg GmbH
Giessen, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Universitätsklinikum Hamburg Eppendorf
Hamburg, Germany
Neurologie Neuer Wall - Dr.Bredow & Partner
Hamburg, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitatsklinikum des Saarlandes
Homburg, Germany
Start Date
August 11, 2025
Primary Completion Date
October 1, 2029
Completion Date
October 1, 2029
Last Updated
March 11, 2026
200
ESTIMATED participants
Efgartigimod PH20 SC
BIOLOGICAL
Lead Sponsor
argenx
NCT06920004
NCT06747351
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06538064